Dr. David W. Martin, Jr., M.D. is the CEO and Chairman of the Board of the parent company, GangaGen Inc. He brings with him valuable experience in the Biotechnology industry with which he has been closely associated for over 20 years.

Most recently Dr. Martin was the CEO of Eos Biotechnology, Inc. a leading, privately held R&D company in the field of genome-based therapeutic antibodies. Dr. Martin started his career at the University of California San Francisco where he taught for 13 years and was Professor of Medicine and Professor of Biochemistry. He was also an Investigator of the Howard Hughes Medical Institute for 8 years. Dr. Martin was recruited in 1983 to join Genentech where he became the first Vice President of Research and Development. In 1990, Dr. Martin was appointed Executive Vice President of R&D at DuPont Merck Pharmaceutical Company. In 1994, Dr. Martin became President of Chiron Therapeutics and Sr. V.P. of Chiron Corporation. Dr. Martin co-founded Eos in 1997, and served as CEO of the company for the past 6 years until it was sold to Protein Design Labs Inc. in April 2003. He serves as a member of the Board of Directors of Varian Medical System and of Cubist Pharmaceuticals.

Mr. Kirkpatrick is Vice President and Managing Director of Research Corporation Technologies (RCT) where he designs and implements programs for developing early stage life science technologies from universities and research institutes. Most of these programs are implemented in the form of a new company with the purpose of commercializing a novel platform technology in biotechnology. Mr. Kirkpatrick's experience and training, both in economics and molecular biology, enable him to consider a range of technical and market issues when designing and managing the new ventures. In addition to overseeing direct financial investments, he plays an active role in creating new companies around platform technologies and then serving as the executive management during the incubation phase. At RCT, Kirkpatrick has been involved with creating and funding several startup companies and ventures such as Therapeutic Human Polyclonals Inc., Sertoli Technologies Inc., Prolifia Inc. and a joint venture with Abgenix Inc. developing antibodies to CD45.

Brent began his tenure at Canaan through the Kauffman Fellows Program in July 1999 and subsequently joined the Canaan staff in November 2000.

Prior to Canaan, Brent worked for a venture-backed medical device company, GSI, where he managed business development, marketing, and sales efforts. In addition to his experience at GSI, he also worked for the Ethicon Endo-Surgery division of Johnson & Johnson where he was involved with the development and launch of numerous products that generate annual revenue in excess of $35 million. In addition to his life sciences experience, Brent spent five years as a Senior Research Engineer at IAP Research, developing a variety of electromagnetic technologies for both defense and commercial applications.

Brent earned his BS and MS degrees in Mechanical Engineering from the University of Dayton and an MBA from the Amos Tuck School of Business at Dartmouth College. Brent is a Professional Engineer and is the holder of three patents relating to medical technologies. He currently serves on the Board of Directors at CardioVention, Coapt Systems, DexCom, Novare Surgical, Peninsula Pharmaceuticals, Revivant, and UltraGuide.